SU-DHL-2

SU-DHL-2/SU-DHL-2细胞系/SU-DHL-2细胞株/SU-DHL-2人弥漫性组织淋巴瘤细胞

Cell line name SU-DHL-2

Synonyms SUDHL2; SUDHL-2; Su-DHL-2; SU-DHL2; SuDHL 2; Stanford University-Diffuse Histiocytic Lymphoma-2; DHL-2

Accession CVCL_9550

Resource Identification Initiative To cite this cell line use: SU-DHL-2 (RRID:CVCL_9550)

Comments Population: Caucasian.

Doubling time: ~24 hours (DSMZ=ACC-902).

Omics: Transcriptome analysis by microarray.

Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.

Sequence variations

Mutation; HGNC; 7562; MYD88; Simple; p.Ser209Arg (c.627T>G) (p.Ser222Arg, c.666T>G) (S222R); Zygosity=Heterozygous (PubMed=21179087).

Disease Diffuse large B-cell lymphoma activated B-cell type (NCIt: C36081)

Diffuse large B-cell lymphoma (ORDO: Orphanet_544)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Sex of cell Female

Age at sampling 73Y

Category Cancer cell line

STR profile Source(s): ATCC=CRL-2956; DSMZ=ACC-902

 

Markers:

Amelogenin X

CSF1PO 12

D2S1338 17,24

D3S1358 14,19

D5S818 13

D7S820 11,13

D8S1179 13

D13S317 11,12

D16S539 14

D18S51 11

D19S433 12

D21S11 30

FGA 21,26

Penta D 13

Penta E 7,11

TH01 6,9

TPOX 8

vWA 17

 

Run an STR similarity search on this cell line

Publications

PubMed=4140017; DOI=10.1002/1097-0142(197412)34:6<1851::AID-CNCR2820340602>3.0.CO;2-4

Epstein A.L., Kaplan H.S.

Biology of the human malignant lymphomas. I. Establishment in continuous cell culture and heterotransplantation of diffuse histiocytic lymphomas.

Cancer 34:1851-1872(1974)

 

PubMed=214220; DOI=10.1002/1097-0142(197811)42:5<2379::AID-CNCR2820420539>3.0.CO;2-4

Epstein A.L., Levy R., Kim H., Henle W., Henle G., Kaplan H.S.

Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines.

Cancer 42:2379-2391(1978)

 

PubMed=83902; DOI=10.1002/1097-0142(197901)43:1<1::AID-CNCR2820430102>3.0.CO;2-M

Kaplan H.S., Goodenow R.S., Gartner S., Bieber M.M.

Biology and virology of the human malignant lymphomas: 1st Milford D Schulz Lecture.

Cancer 43:1-24(1979)

 

PubMed=371794

Epstein A.L., Kaplan H.S.

Feeder layer and nutritional requirements for the establishment and cloning of human malignant lymphoma cell lines.

Cancer Res. 39:1748-1759(1979)

 

PubMed=3881165; DOI=10.1016/0165-4608(85)90186-4

Kaiser-McCaw Hecht B., Epstein A.L., Berger C.S., Kaplan H.S., Hecht F.

Histiocytic lymphoma cell lines: immunologic and cytogenetic studies.

Cancer Genet. Cytogenet. 14:205-218(1985)

 

PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x

Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G., Uppenkamp M.J., Nowrousian M.R., Seeber S., Opalka B.

Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines.

Br. J. Haematol. 91:350-354(1995)

 

PubMed=15356658; DOI=10.1038/sj.leu.2403465

Drexler H.G., MacLeod R.A.F.

Malignant hematopoietic cell lines: in vitro models for the study of anaplastic large-cell lymphoma.

Leukemia 18:1569-1571(2004)

 

PubMed=21179087; DOI=10.1038/nature09671; PMCID=PMC5024568

Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W.-M., Lim K.-H., Kohlhammer H., Xu W.-H., Yang Y.-D., Zhao H., Shaffer A.L. 3rd, Romesser P.B., Wright G., Powell J.I., Rosenwald A., Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.-C., Staudt L.M.

Oncogenically active MYD88 mutations in human lymphoma.

Nature 470:115-119(2011)